000 04049nam a22005295i 4500
001 60103
005 20200226102452.0
007 cr nn 008mamaa
008 170109s2017 gw | s |||| 0|eng d
020 _a9783319427690
_9978-3-319-42769-0
024 7 _a10.1007/978-3-319-42769-0
_2doi
035 _a(DE-He213)978-3-319-42769-0
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
245 1 0 _aManagement of Prostate Cancer
_h[electronic resource] :
_bA Multidisciplinary Approach /
_cedited by Michel Bolla, Hendrik van Poppel.
250 _a2nd ed. 2017.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2017.
300 _aVIII, 422 p. 76 illus., 64 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aEpidemiology of prostate cancer in Europe -- Chemoprevention -- Individual and mass screening -- Anatomo-pathology -- Biology -- Genomics -- Radiologic investigations( multiparametric MRI, whole body MRI) -- Nuclear Medecine: follow-up (Choline PET-CT, Radium 223)and treatment of bone metastases -- Diagnosis, clinical work up, TNM classification Markers -- Active surveillance -- Open Radical Prostatectomy -- The robotic laparoscopic radical prostatectomy -- Brachytherapy (Low dose rate) -- Brachytherapy (High dose rate) -- IMRT, hypofractionated irradiation and stereotactic irradiation -- External irradiation + androgen suppression -- Post-operative irradiation: immediate or early delayed?- High Intensity Focused Ultrasound -- Cryotherapy -- Follow-up after radical treatments* and relapse -- First line hormonal manipulations -- Upfront chemotherapy at initiation of hormonal treatment for metastatic prostate cancer -- Bone-targeted therapies (Bisphosphonates, denosumab and Radium 223 -- Targeted therapies and vaccination -- How to interprete results -- Prostate EAU guidelines -- Better Patients perspective.
520 _aThis book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT. The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient’s perspective.
650 0 _aMedicine.
650 0 _aCancer research.
650 0 _aRadiotherapy.
650 0 _aOncology.
650 0 _aUrology.
650 0 _aEpidemiology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aUrology.
650 2 4 _aRadiotherapy.
650 2 4 _aEpidemiology.
650 2 4 _aCancer research.
700 1 _aBolla, Michel.
_eeditor.
700 1 _avan Poppel, Hendrik.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783319427683
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-319-42769-0
912 _aZDB-2-SME
999 _c5043
_d5043